CPT 87636: Multiplex SARS-CoV-2, Influenza A and B Detection
CPT code 87636 represents a multiplex molecular diagnostic assay that detects and differentiates SARS–CoV–2, influenza A, and influenza B using an amplified nucleic acid probe technique. This test is central to respiratory infectious disease management and surveillance, enabling simultaneous identification of multiple viral pathogens from a single specimen and supporting timely clinical and public health responses. Nationally, widespread use of multiplex testing affects laboratory workflows, supply chain planning, and payer coverage policies.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, United Healthcare, and Medicare. Readers will find an overview of the clinical purpose of the assay, common billing considerations, typical sites of service, and related procedural context. The publication outlines how this code fits within laboratory service lines, notes related codes for broader respiratory panels, and provides practical metadata for billing and coding teams.
This summary is intended to orient laboratory directors, coding professionals, and health policy stakeholders to the clinical role of CPT code 87636, the payer landscape addressed, and the types of operational and policy topics covered in the full publication, including reimbursement benchmarks, coverage nuances, and clinical context for multiplex respiratory viral testing.
Customize your policy alerts
Sign up for cpt 87636 policy alerts
Get alerted when payer policies referencing 87636 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 87636 describes a laboratory test in which a lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic acid probe technique. This service is a molecular diagnostic assay that identifies multiple respiratory viral agents from a single specimen.
Service type: Multiplex molecular diagnostic testing (technical component)
Typical site of service: Clinical laboratory or hospital laboratory
National Reimbursement Benchmarks
National commercial rates for CPT 87636 cluster around BUCA’s average commercial benchmark of $154.30, with substantial differences among carriers. Blue Cross Blue Shield’s mean of $166.30 and Aetna’s mean of $151.40 sit near BUCA, while Cigna’s mean of $140.60 and UnitedHealth Group’s mean of $122.90 are lower. Maximums vary widely, from Aetna’s $345.20 and Blue Cross Blue Shield’s $324.50 to UnitedHealth Group’s $532.60 and Cigna’s $428.60, indicating occasional high outliers across payers.
Dispersion measured by the interquartile range (P75–P25) highlights where rates are tightest or widest: Blue Cross Blue Shield has the narrowest IQR at $49.70 ($182.50–$132.80), followed closely by Aetna at $13.20 ($155.20–$142.00), while UnitedHealth Group shows the widest spread at $76.10 ($142.80–$66.70). Cigna’s IQR is $95.40 and BUCA’s is $54.60, signaling that contractual variability is most pronounced with UnitedHealth Group and Cigna and relatively contained with Blue Cross Blue Shield and Aetna.